Sorafenib in First-line Treatment of Advanced B Child Hepatocellular Carcinoma

Summary

The purpose of this study is to to compare the addition of sorafenib (800 mg/day)to best supportive care with best supportive care alone in terms of survival in patients with hepatocellular carcinoma (HCC) with impaired liver function (Child B).

Timeline

Start

2011-07

Primary completion

2017-03

Completion

2017-03

Drugs

Indications